The unavoidable tradeoff in lowering drug prices: fewer new drugs

Although House Speaker Nancy Pelosi’s plan to lower prescription drug prices would save the federal government hundreds of billions of dollars, but at what cost? According to a new analysis from the Congressional Budget Office it makes clear the tradeoff for more government intervention in the drug market: Cost savings for the government would equal less spending on research and development by drug companies which mean fewer new treatments. Read article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.